Skip to main content
OpenTrials

Clinical trial condition

Gastroesophageal Junction Adenocarcinoma

Explore clinical trials studying Gastroesophageal Junction Adenocarcinoma. Study availability and eligibility vary by location and protocol.

131 public trials 41 recruiting studies
Refine in advanced search Browse all conditions

Gastroesophageal Junction Adenocarcinoma trial results

Completed

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02864381

Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Locations
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Chicago, Illinois, United States
  • Fort Wayne, Indiana, United States
View all 34 locations
View Trial Details
Completed

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

NCT02443883

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Adenocarcinoma, +7 more
Locations
  • Arizona Clinical Research Center Tucson, Arizona, United States
  • USC Norris Cancer Hospital Los Angeles, California, United States
  • Carolinas Medical Center Charlotte, North Carolina, United States
  • Oklahoma Cancer Specialists & Research Institute, LLC Tulsa, Oklahoma, United States
View all 45 locations
View Trial Details
Completed

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

NCT02514551

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Adenocarcinoma, +7 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of Kansas Medical Center Westwood, Kansas, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Weill Cornell Medical College New York, United States
View all 52 locations
View Trial Details
Completed

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

NCT00515411

Conditions
Adenocarcinoma, Carcinoma, Digestive System Diseases, +11 more
Locations
  • City of Hope Cancer Center Duarte, California, United States
  • Memorial Cancer Institute Pembroke Pines, Florida, United States
  • Piedmont Hospital Research Institute Atlanta, Georgia, United States
  • Nebraska Cancer Specialists, Methodist Estabrook Cancer Center Omaha, Nebraska, United States
View all 15 locations
View Trial Details
Active, Not Recruiting

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

NCT05476796

Conditions
Adenocarcinoma, Adenocarcinoma Of Esophagus, Carcinoma, +12 more
Locations
  • Clinique de l'Europe Amiens, France
  • Hopital Privé Arras Les Bonnettes Arras, France
  • Institut Sainte Catherine Avignon, France
  • Centre Hospitalier de Beauvais Beauvais, France
View all 28 locations
View Trial Details
Active, Not Recruiting

A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

NCT06243757

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Cancer, +8 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All protocol activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack (All Protocol Activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892

Conditions
Advanced Breast Cancer, Advanced Gastric Cancer, Breast Diseases, +17 more
Locations
  • Banner-University Medical Center Tucson Campus Tucson, Arizona, United States
  • Banner-University Medical Center Tucson Campus Tucson, Arizona, United States
  • The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal Tucson, Arizona, United States
  • University of Arizona Cancer Center - North Campus Tucson, Arizona, United States
View all 135 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310

Conditions
Adenocarcinoma Of Esophagus, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, +1 more
Locations
  • City of Hope National Medical Center /ID# 268690 Duarte, California, United States
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 272630 Irvine, California, United States
  • UCLA - Santa Monica /ID# 270024 Santa Monica, California, United States
  • AdventHealth Orlando /ID# 268561 Orlando, Florida, United States
View all 49 locations
View Trial Details

Related conditions